Healthcare provider profile · identity verified

Jimmy Bui, D.O.

Internal Medicine · OKLAHOMA CITY, OK · NPI 1649653833

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	353	95
Atorvastatin Calcium	Atorvastatin Calcium	294	130
Furosemide	Furosemide	268	115
Amlodipine Besylate	Amlodipine Besylate	258	119
Gabapentin	Gabapentin	228	109
Levothyroxine Sodium	Levothyroxine Sodium	194	88
Pantoprazole Sodium	Pantoprazole Sodium	187	99
Potassium Chloride	Potassium Chloride	183	87
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	155	88
Tamsulosin Hcl	Tamsulosin Hcl	153	67
Carvedilol	Carvedilol	135	69
Lisinopril	Lisinopril	113	52
Sertraline Hcl	Sertraline Hcl	108	44
Trazodone Hcl	Trazodone Hcl	107	44
Metoprolol Tartrate	Metoprolol Tartrate	105	49
Metformin Hcl	Metformin Hcl	92	38
Omeprazole	Omeprazole	83	38
Duloxetine Hcl	Duloxetine Hcl	82	41
Clopidogrel	Clopidogrel Bisulfate	80	46
Metoprolol Succinate	Metoprolol Succinate	79	46
Mirtazapine	Mirtazapine	76	26
Torsemide	Torsemide	73	24
Famotidine	Famotidine	69	22
Buspirone Hcl	Buspirone Hcl	68	36
Losartan Potassium	Losartan Potassium	65	40
Hydralazine Hcl	Hydralazine Hcl	64	24
Allopurinol	Allopurinol	63	29
Jardiance	Empagliflozin	63	14
Donepezil Hcl	Donepezil Hcl	61	22
Montelukast Sodium	Montelukast Sodium	56	23
Oxycodone Hcl	Oxycodone Hcl	51	28
Quetiapine Fumarate	Quetiapine Fumarate	51	14
Amiodarone Hcl	Amiodarone Hcl	48	24
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	48	32
Levetiracetam	Levetiracetam	45	25
Levofloxacin	Levofloxacin	45	41
Hydroxyzine Hcl	Hydroxyzine Hcl	44	22
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	12
Pravastatin Sodium	Pravastatin Sodium	44	21
Simvastatin	Simvastatin	44	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	16
Divalproex Sodium	Divalproex Sodium	42	12
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	42	20
Citalopram Hbr	Citalopram Hydrobromide	41	15
Olanzapine	Olanzapine	41	12
Albuterol Sulfate Hfa	Albuterol Sulfate	40	23
Tramadol Hcl	Tramadol Hcl	39	30
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	12
Ondansetron Hcl	Ondansetron Hcl	36	27
Prednisone	Prednisone	36	28
Pregabalin	Pregabalin	36	23
Escitalopram Oxalate	Escitalopram Oxalate	35	20
Isosorbide Dinitrate	Isosorbide Dinitrate	35	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	34	18
Midodrine Hcl	Midodrine Hcl	34	19
Oxybutynin Chloride	Oxybutynin Chloride	34	17
Ropinirole Hcl	Ropinirole Hcl	34	18
Finasteride	Finasteride	33	14
Spironolactone	Spironolactone	33	18
Memantine Hcl	Memantine Hcl	30	18
Methocarbamol	Methocarbamol	30	25
Rosuvastatin Calcium	Rosuvastatin Calcium	30	14
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Clonidine Hcl	Clonidine Hcl	28	12
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Temazepam	Temazepam	28	suppressed
Xarelto	Rivaroxaban	27	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	21
Aripiprazole	Aripiprazole	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	25	21
Insulin Aspart Flexpen	Insulin Aspart	25	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	12
Clonazepam	Clonazepam	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Risperidone	Risperidone	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	21
Ibuprofen	Ibuprofen	23	11
Venlafaxine Hcl Er	Venlafaxine Hcl	23	11
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Latanoprost	Latanoprost	22	suppressed
Meclizine Hcl	Meclizine Hcl	22	suppressed
Prazosin Hcl	Prazosin Hcl	22	suppressed
Fluticasone Propionate	Fluticasone Propionate	21	14
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	21	suppressed
Morphine Sulfate Er	Morphine Sulfate	21	14
Atenolol	Atenolol	20	suppressed
Megestrol Acetate	Megestrol Acetate	20	14
Linzess	Linaclotide	19	suppressed
Dexamethasone	Dexamethasone	18	18
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Baclofen	Baclofen	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	17	suppressed
Lactulose	Lactulose	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Sucralfate	Sucralfate	17	14
Topiramate	Topiramate	17	suppressed
Alprazolam	Alprazolam	16	13
Cephalexin	Cephalexin	16	16
Colchicine	Colchicine	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	11
Brilinta	Ticagrelor	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Bethanechol Chloride	Bethanechol Chloride	13	suppressed
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	13	suppressed
Dropsafe Pen Needle	Pen Needle, Diabetic, Safety	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Copaxone	Glatiramer Acetate	12	suppressed
Glipizide	Glipizide	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Calcium Acetate	Calcium Acetate	11	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Metronidazole	Metronidazole	11	11
Primidone	Primidone	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error